<DOC>
	<DOC>NCT02759354</DOC>
	<brief_summary>To describe long-term persistence of Hepatitis B and pertussis antibody responses in healthy 4- to 5 Year old children previously vaccinated with VAXELIS or INFANRIX hexa</brief_summary>
	<brief_title>Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With VAXELIS or INFANRIX Hexa</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria 1. Healthy child of either gender, who has received a complete 3dose primary series or a complete 2 dose primary series followed by a toddler dose with VAXELIS or INFANRIX hexa as part of the V419007 or V419008 study respectively; 2. Informed consent signed by the subject's parent(s) or legal representative. 1. Subject who has received any dose of HB containing vaccine at any time other than study vaccine in V419007 or V419008 study; 2. Subject with a history of diagnosis (clinical, serological or microbiological) of HB virus infection of the V419007 or V419008 study; 3. Subject who has received any dose of pertussis containing vaccine after completion of the V419008 study; 4. Subject with a history of diagnosis (clinical, serological or microbiological) of infection due to pertussis after completion of V419008 study; 5. Participation at the time of study enrolment or in the 4 weeks preceding the study enrolment in another clinical study investigating a vaccine, drug medical device, or medical procedure; 6. Subject who received immunoglobulins, blood or bloodderived products within 3 months prior to inclusion; 7. Receipt of immunosuppressive therapy or other immunemodifying drugs, such as anticancer chemotherapy or radiation therapy since completion of V419007 or V419008 studies; 8. Subject with suspected or known blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the haematopietic and lymphatic systems since completion of V419007 or V419008 studies.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immune response</keyword>
</DOC>